Rocket Lab Files Pro Forma Financials for $7.6B Iridium Acquisition, Reveals $3.6B Bridge Loan
RKLB has more than doubled off its 52-week low of $37.57.
Summary
Rocket Lab filed pro forma financials for its $7.6 billion Iridium acquisition, revealing a $3.6 billion bridge loan at 8% interest and pro forma net losses of $154.7M for H1 2026.
Key Events · M&A and Partnerships · RKLB
-
Pro Forma Financials Filed
Combined pro forma revenue of $878.7M for H1 2026 and $1.47B for FY2025; pro forma net loss of $154.7M for H1 2026 and $203.0M for FY2025.
-
$3.6B Bridge Loan Disclosed
364-day senior secured bridge term loan from Deutsche Bank and Wells Fargo at approximately 8.0% effective interest rate, adding $141.4M interest expense for H1 2026 and $285.7M for FY2025.
-
Purchase Price Allocation
Total estimated consideration of $7.59B: $2.86B cash, $2.86B stock (41.26M shares at $69.33 VWAP), $93.8M equity awards, and $1.77B debt payoff. Goodwill of $2.20B and intangibles of $4.33B (including $3.32B spectrum).
-
Exchange Ratio Mechanics
Exchange ratio of 0.4000 if RKLB price ≤ $67.50; 0.2400 if ≥ $112.50; variable between $67.50 and $112.50. Current 10-day VWAP of $69.33 yields ratio of 0.3894.
Analysis · RKLB · Manufacturing
This 8-K provides the first detailed pro forma financial statements for the pending Iridium acquisition, quantifying the combined entity's revenue, losses, and balance sheet. It also discloses the $3.6 billion bridge loan facility at an 8% effective interest rate, which will significantly increase interest expense and contribute to pro forma net losses of $154.7 million for H1 2026 and $203.0 million for FY2025. The purchase price allocation shows $2.2 billion in goodwill and $4.3 billion in intangible assets, including $3.3 billion for spectrum. These details give investors a clearer picture of the deal's financial impact, including the substantial debt burden and dilution from issuing 41.3 million shares.
At the time of this filing, RKLB was trading at $80.37 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $48.6B. The 52-week trading range was $37.57 to $151.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.